Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial

Lung Cancer

Volumn 37, Issue 2, 2002, Pages 189-199

  Robert, Francisco ^a,b   Spencer, Sharon A ^c   Childs III, Hoyt A ^c   Zhang, Ruiwen ^d   Meredith, Ruby F ^c   Wheeler, Richard H ^e   Hawkins, Martha H ^c   Carey, Delicia ^f  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c The University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemoradiotherapy; Cisplatin; Non small cell lung cancer

Indexed keywords

CISPLATIN; PACLITAXEL; STEROID; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGITIS; EVALUATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PATIENT SELECTION; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; STEROID THERAPY; ADOLESCENT; LUNG FUNCTION TEST; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; NEOPLASM STAGING; PACLITAXEL; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE; HUMANS; MIDDLE AGED;

EID: 0036021971     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00029-6     Document Type: Article

References (36)

1. Lung cancer in patients with borderline lung functions zonal lung perfusion scans at presentation and lung function after high dose irradiation
2. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: The Eastern cooperative oncology group results
3. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer
4. The role of curative radiotherapy in treatment of lung cancer
5. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
6. New chemotherapeutic agents in non-small cell lung cancer
7. Lung
8. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
9. Confirmation of dose-volume histograms and normal tissue complication probability calculation to predict pulmonary complications after radiotherapy for lung cancer
10. Predicting radiation response
11. The importance of dose intensity in chemotherapy of metastatic breast cancer
12. Randomized trial of hyerfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
13. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 352 patients
14. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer
15. The pulmonary effects of thoracic irradiation
16. Physical and biological predictors of changes in whole-lung function following thoracic irradiation
17. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
18. A new international staging system for lung cancer
19. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer
20. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung
21. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer
22. Pulmonary toxicity and combined modality therapy
23. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer
24. Sequences of taxol and cisplatin: A phase I and pharmacologic study
25. Microtubule changes and cytotoxicity in leukemic cell line treated with taxol
26. Taxol: A novel investigational antineoplastic agent
27. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin
28. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (EGOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer
29. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
30. Radiosensitization by taxol of a human ovarian cancer cell line
31. Taxol sensitizes human astrocytoma cells to radiation
32. Rapid repopulation in radiotherapy: A debate on mechanism, accelerated repopulation in tumors and normal tissues
33. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (taxol) in human plasma